Add to ORKGIntroduction: Rilpivirine (RPV) has a better lipid profile than efavirenz (EFV) in naı̈ve patients [1]. Switching to RPV may be convenient for many patients, while maintaining a good immunovirological control [2]. The aim of this study was to analyze lipid changes in HIV-patients at 24 weeks after switching to Eviplera † (emtricitabine/RPV/tenofovir disoproxil fumarate [FTC/RPV/ TDF]). Materials and Methods: Retrospective, multicentre study of a cohort of asymptomatic HIV-patients who switched from
This study aimed to evaluate the efficacy, tolerability and potential savings of combined antiretrov...
International audienceBackground. The purpose of this study was to assess the efficacy and tolerabil...
International audienceTenofovir disoproxil fumarate is a prodrug of tenofovir diphosphate that expos...
Meeting abstract. Abstracts of the HIV Drug Therapy Glasgow Congress 2014INTRODUCTION Rilpivirine (...
Introduction: Rilpivirine (RPV) has a better lipid profile than efavirenz (EFV) in naïve patients (1...
Abstract Background Dyslipidemia represents a significant non-infectious comorbidity among people li...
Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), bu...
Drug choice and metabolic changes with antiretroviral therapy contribute to cardiovascular risk in p...
Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), b...
To analyse lipid changes and tolerability in a cohort of HIV-infected patients who switched their an...
BACKGROUND:Drug choice and metabolic changes with antiretroviral therapy contribute to cardiovascula...
Background Drug choice and metabolic changes with antiretroviral therapy contribute to cardiovascula...
Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), bu...
Abstract Background We aimed to assess the overall cardiovascular and metabolic effect of the switch...
In the era of combination antiretroviral therapy (ART), people living with HIV (PLHIV) still face an...
This study aimed to evaluate the efficacy, tolerability and potential savings of combined antiretrov...
International audienceBackground. The purpose of this study was to assess the efficacy and tolerabil...
International audienceTenofovir disoproxil fumarate is a prodrug of tenofovir diphosphate that expos...
Meeting abstract. Abstracts of the HIV Drug Therapy Glasgow Congress 2014INTRODUCTION Rilpivirine (...
Introduction: Rilpivirine (RPV) has a better lipid profile than efavirenz (EFV) in naïve patients (1...
Abstract Background Dyslipidemia represents a significant non-infectious comorbidity among people li...
Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), bu...
Drug choice and metabolic changes with antiretroviral therapy contribute to cardiovascular risk in p...
Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), b...
To analyse lipid changes and tolerability in a cohort of HIV-infected patients who switched their an...
BACKGROUND:Drug choice and metabolic changes with antiretroviral therapy contribute to cardiovascula...
Background Drug choice and metabolic changes with antiretroviral therapy contribute to cardiovascula...
Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), bu...
Abstract Background We aimed to assess the overall cardiovascular and metabolic effect of the switch...
In the era of combination antiretroviral therapy (ART), people living with HIV (PLHIV) still face an...
This study aimed to evaluate the efficacy, tolerability and potential savings of combined antiretrov...
International audienceBackground. The purpose of this study was to assess the efficacy and tolerabil...
International audienceTenofovir disoproxil fumarate is a prodrug of tenofovir diphosphate that expos...